Koji Kabuto
- Giugno 7, 2025
- 0 Comments
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 – Sarepta Therapeutics
The U.S. Food and Drug Administration (FDA) has granted platform technology designation to the viral vector used in SRP-9003, Sarepta Therapeutics’ in…
Leggi tutto
